Gapping down
News:
- ITOS -13.6% (Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients)
- VZLA -11% (reports updates for its at-the-market equity program; announces $65 million bought deal financing)
- GH -9.5% (after EXAS Colorectal Cancer Screening update)
- UPST -4.4% (to propose private offering of $300,000,000 aggregate principal amount of Convertible Senior Notes due 2029)
- TIL -4.2% (Instil Bio and ImmuneOnco announce global registrational strategy for PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, in non-small cell lung cancer and triple-negative breast cancer)
- BFH -2.3% (Provides Performance Update for August)
- IMTX -2.2% (Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update)
- BDTX -1.5% (Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress)
- TPG -1.2% (files for 53,004,985 shares of Class A common stock offering)
- AL -1.1% (confirms it was notified by The Boeing Company (BA) that certain union factory workers announced a labor strike )
- APLD -1% (files for offering of 6,300,449 shares of common stock underlying the warrant issued to a single institutional investor)
- MXCT -1% (signs strategic platform license with Kamau Therapeutics)
- NUVB -1% (Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024)